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Abstract – The cyclocondensations of 3,4-dihydroquinazolin-2-yl guanidine with 
a variety of electrophilic reagents viz. aldehydes, ketones, triethyl orthoformate, 
diethyl ethoxymethylenemalonate, carbon disulfide and trichloroacetonitrile were 
found to afford 1,3,5-triazino[2,1-b]quinazolines. However, some unexpected 
reactions were also observed. The structural properties such as tautomerism and 
hinderance to conformational rotation were also investigated. The results of 
biological testing suggested that the 1,3,5-triazino[2,1-b]quinazoline nucleus could 
be a new promising scaffold for the development of potential anticancer agents. 
INTRODUCTION  
In our previous studies2 we found that the heterocyclization of benzimidazol-2-yl guanidines (1) with 
one-carbon inserting reagents afforded 1,3,5-triazino[1,2-a]benzimidazoles, particularly 
2-amino-4,4-dimethyl-3,4-dihydro[1,3,5]triazino[1,2-a]benzimidazole (2) (Fig. 1), which was able to 























In order to extend this methodology to the synthesis of structurally similar 1,3,5-triazinoquinazolines with 
potential anticancer activity, we report here the preparation of 3,4-dihydroquinazolin-2-yl guanidine (3) 
(Fig. 1) and its reactions with a variety of elecrophiles.  
Information on the synthesis of 1,3,5-triazinoquinazolines is limited. In general, three isomeric structures 
are possible for quinazoline fused with 1,3,5-triazine nucleus, viz. 1,3,5-triazino[1,2-a]quinazoline (A),3 
1,3,5-triazino[2,1-b]quinazoline (B)4 and 1,3,5-triazino[1,2-c]quinazoline (C)4a, 5 heterocyclic systems (Fig. 
2). The cyclization of 3,4-dihydroquinazolin-2-yl guanidine (3) might hypothetically result in the formation 
of systems A or B. In previous study, we also found that cyclization of unsymmetrically substituted in the 
phenylene fragment benzimidazol-2-yl guanidines (1, R ≠ H) with one-carbon inserting reagents did not 
proceed regioselectively.2a Therefore, regioselectivity of the ring closure of 3 became one of the important 
aspects of our investigation. With regards to DHFR inhibitory activity of 22 and antiproliferative properties 
of other structurally related fused 1,3,5-triazines synthesized in our laboratory6, we also report herein the 























A B C  
Figure 2 
RESULTS AND DISCUSSION  
Synthesis 
3,4-Dihydroquinazolin-2-yl guanidine (3) was prepared using acid catalyzed cyclocondensation of 









i:  H2NC(=NH)NHCN, HCl, H2O, reflux, 18 h;




















Broadening of the signals of C-2, C-4, C-8 and C-8a atoms observed in 13C NMR spectrum of 3 indicated 
the existence of dihydroquinazolin-2-yl guanidine in equilibrium of two forms 3 and 3’ due to annular 
 
tautomerism. The presence of tautomeric form 3’’ in the equilibrium was less probable as no broadening for 
the signal of the guanidine group carbon atom in the 13C NMR spectrum was detected. 
In our attempt to prepare an analogue of bioactive compound 2, 3,4-dihydroquinazolin-2-yl guanidine (3) 
was heated in acetone under piperidine catalysis. The 1,3,5-triazine ring closure reaction resulted in the 
formation of product with two geminal methyl groups for which two alternative structures 5 and 6 could be 
attributed (Scheme 2). The formation of the dihydro-1,3,5-triazine ring with sp3 hybridized quarternary 
carbon atom was confirmed by the presence of signals at 71.2 ppm in 13C NMR spectrum. 2D NOESY 
experiments showed cross-peaks between the singlets of the gem-dimethyl groups and the methylenic 
protons of dihydroquinazoline nucleus indicating their close proximity. These observations confirmed the 
annelation of the triazine ring to side b of quinazoline and led to the assignment of the 
2-amino-4,4-dimethyl-4,6-dihydro-1(3)(11)H-[1,3,5]triazino[2,1-b]quinazoline (5) structure for the 


























The reaction of 3,4-dihydroquinazolin-2-yl guanidine (3) with (het)arylaldehydes proceeded via (5+1) 
heterocyclization with the formation of 2-amino-4-(het)aryl-4,6-dihydro-1(3)(11)H-[1,3,5]triazino- 
[2,1-b]quinazolines (7) (Scheme 3). The reaction was found to be general and regioselective. The signal of 
the sp3-hybridized carbon atom at 70-74 ppm in the 13C NMR spectra indicated the ring closure with the 
formation of dihydro-1,3,5-triazine nucleus. Another evidence of the cyclization was a coupling 
(Jgem ≈ 14.5 Hz) of the signals of methylenic protons of the dihydroquinazoline ring in 
1H NMR spectra of 
the products 7. These protons became diastereotopic and their signals appeared as two doublets of AM 
system at 3.90-4.20 and 4.25-4.40 ppm. The dihydro-1,3,5-triazine ring fusion on side b of the quinazoline 
was confirmed by cross-peaks found in 2D NOESY experiments for the signals of methylenic protons and 
the singlet of proton at newly introduced sp3-hybridized carbon of the nucleus.  
 
Compound R Yield, % Compound R Yield, %
7a Ph 85 7e 4-MeOC6H4 58
7b 4-ClC6H4 84 7f 4-Me2NC6H4 75
7c 4-BrC6H4 87 7g 2-Thienyl 82


















The annular prototropic tautomerism was noticed in DMSO solution for compounds 5 and 7 viz. 1H-, 3H- 
and 11H-tautomeric forms (Scheme 4). The prototropic interconversion between these tautomeric forms 
was postulated based on broadening observed for several signals of 
4,6-dihydro-1(3)(11)H-[1,3,5]triazino[2,1-b]quinazoline heterocyclic system in the 13C NMR spectra of 
compounds 5 and 7. The pattern of the signal broadening indicated that all three tautomeric forms were 
involved in the proton transfer. The broadening of C-4 signal referred to the 1H- / 3H- equilibrium and the 
























Heating cycloketones (e.g. cyclopentanone and cyclohexanone) with benzimidazol-2-yl guanidine (1, 
R = H) in DMF has been shown to provide spiro-fused 1,3,5-triazines.2b, 7 When similar conditions were 
applied for the reaction of 3 with these ketones, the formation of fused 1,3,5-triazines (8) with similar 
structure was expected (Scheme 5). However, instead of dihydrotriazine ring closure, the reaction furnished 
the formation of compounds 9 with pyrimidine ring constructed from guanidine moiety, two carbon atoms 










n = 1 (9a), 46%; 2 (9b), 62%


















Orthoesters are well known as one-carbon inserting reagents in heterocyclic chemistry for a long time.8 The 
reaction of 3 with triethyl orthoformate proceeded regioselectively with the 1,3,5-triazine ring closure onto 
side b of the dihydroquinazoline affording 2-amino-6H-1,3,5-triazino[2,1-b]quinazoline (10) (Scheme 6). 
This was confirmed by the observation of cross-peaks between the signals of methylenic protons of 
quinazoline and methine proton of triazine ring in 2D NOESY experiment. 1H NMR spectrum of 10 
showed two separate D2O exchangeable signals at 7.20 and 7.24 ppm corresponding to the amino group. 
The magnetic unequivalence of the amino group protons can be explained on the basis of strong π-electrons 
delocalization of the amino group with the 1,3,5-triazine ring9 that resulted in increasing rotational barrier. 
The activation energy (ΔG‡308) for the rotation around C-NH2 bond was found to be 70.6 kJ/mol as 
estimated by dynamic NMR experiments.  
Diethyl ethoxymethylenemalonate as a potential triatomic synthon10 might theoretically react with 
guanidine moiety providing 11 (Scheme 6). However, likewise in the reaction with benzimidazol-2-yl 
guanidines (1),2 diethyl ethoxymethylenemalonate reacted with 3 playing a role of one-carbon inserting 
reagent affording the formation of 10. The reaction proceeded with elimination of ethanol and diethyl 





























Carbon disulfide has been recognized as valuable reagent in organic chemistry, particularly useful for 
thiocarbonylation reactions.11 The ring closure thiocarbonylation of 3 with carbon disulfide was 
 
successfully achieved (Scheme 7) using the method described by Martin et al.7 for structurally related 
benzimidazol-2-yl guanidine (1, R = H). The structure of the product (12) was confirmed by spectroscopic 
data. The presence of the thioxo group at C-4 was supported with a significant stretching absorption at 
1186 cm-1 in the IR spectrum of compound 12 and signal at 182.8 ppm in the 13C NMR spectrum for this 
atom. The anisotropic effect of the thioxo group caused a downfield shift of the signal of methylenic 




















Trichloroacetonitrile has been known as a useful synthon in heterocyclic chemistry,12 particularly it has 
found an application as one-carbon inserting reagent for the construction of 1,3,5-triazine ring introducing 
tricloromethyl or amino group.13 We found that 3 reacted with trichloroacetonitrile in ethanol with 












































X =  - (1, 15a and 16a), CH2 (3, 15b and 16b)
16a, 72%; 16b, 68%
 
Scheme 8 
Similarly, benzimidazol-2-yl guanidine (1) under the same reaction conditions provided 
2,4-diamino-1,3,5-triazino[1,2-a]benzimidazole (15a), which was identical to the compound prepared via 
 
alternative synthetic pathway from 2-aminobenzimidazole (13) and cyanoguanidine according to the 
method reported by Kreutzberger and Tantawy.14 The reactions of trichloroacetonitrile with 
heterylguanidines (1 and 3) in ethanol were found to proceed chemo- and regioselectively affording with 
good yields 15, exclusively; no traces of possible alternative product 14 were detected. Therefore, 
trichloroacetonitrile could be considered as a safer replacement of cyanogen bromide used in this type of 
reactions.7  
Due to solubility problem, compounds 15 were converted into their hydrochloric salts. In both cases, the 
protonation occurred at endocyclic nitrogen atom not belonging to the triazine ring that was confirmed by 
2D NOESY experiment data (cross-peaks between signals of N+H and phenylene proton). Additionally, for 
compound 16b, the cross-peaks observed between the singlet of methylenic protons at 5.12 ppm and the 
signals of one of the amino groups at 7.76-7.78 ppm confirmed the regiochemistry of the triazine ring 
closure to side b of quinazoline nucleus. The same cross-peaks also facilitated the assignments of signals of 
the amino groups for this compound.  
The hindered rotation was detected for the amino groups of 16. The activation energy (ΔG‡) of the rotation 
around C(2)-NH2 bond was estimated for compounds 16 using dynamic 
1H NMR spectroscopy. For 
2,4-diamino-1,3,5-triazino[1,2-a]benzimidazole hydrochloride (16a), the value of ΔG‡333 was equal 
71.4 kJ/mol; for 2,4-diamino-6H-1,3,5-triazino[2,1-b]quinazoline (10), ΔG‡320 was found to be 
73.6 kJ/mol.  
Biological activity 
The antiproliferative activity of the prepared 1,3,5-triazino[2,1-b]quinazolines against lung (A549) and 
breast (MDA-MB-231) cancer cell lines was evaluated using MTT assay.15 4-(Het)aryl substituted 
2-amino-4,6-dihydro-1(3)(11)H-[1,3,5]triazino[2,1-b]quinazolines (7) were the only group of compounds 
which possessed antiproliferative activity in micromolar range (Table 1). This is the first time, anticancer 
activity was reported for compounds with 1,3,5-triazino[2,1-b]quinazoline scaffold. The antiproliferative 
activity of the compounds (7) seemed to depend on their lipophilicity. The more lipophilic halogen 
substituted 7b and 7c showed higher antiproliferative effect.  
In the enzyme assay, no significant effect on the human DHFR activity was observed in the presence of the 
compounds at 100 μM. Therefore, the effect of the compounds on the growth of cancer cells was not 
associated with DHFR inhibition.  
CONCLUSION 
New 1,3,5-triazino[2,1-b]quinazolines were effectively prepared via cyclocondensation of 
3,4-dihydroquinazolin-2-yl guanidine (3) with variety of one-carbon inserting reagents. The reactions were 
 
found to be chemo- and regioselective. The 1,3,5-triazino[2,1-b]quinazoline nucleus was identified as a 
new scaffold for the development of potential anticancer agents.  
 
Table 1. Antiproliferative activity of some  
2-amino-4-(het)aryl-4,6-dihydro-1(3)(11)H-[1,3,5]triazino[2,1-b]quinazolines (7) 
GI50, μM Compound R 
MDA-MB-231 A549 
7a Ph 93 110 
7b 4-ClC6H4 27 33 
7c 4-BrC6H4 17 15 
7d 4-MeC6H4 61 33 
7e 4-MeOC6H4 98 40 
7f 4-Me2NC6H4 53 27 
7g 2-Thienyl 92 104 
7h 3-Py > 100 > 100 
 
EXPERIMENTAL 
General Methods. Melting points (uncorrected) were determined on a Gallenkamp melting point 
apparatus. The IR spectra were recorded with a Shimadzu IRPrestige-21 spectrophotometer using KBr 
pellets. 1H and 13C NMR spectra were recorded on a Bruker DPX-300 spectrometer, using DMSO-d6 as a 
solvent and TMS as an internal reference. The dynamic NMR experiments were performed using 0.5 M 
solutions of the compounds in DMSO-d6.  
 
1(3),4-Dihydroquinazolin-2-yl guanidine (3). 
2-Aminobenzylamine (4, 5.0 g, 41 mmol) and cyanoguanidine (4.3 g, 51 mmol) were dissolved in 15 mL of 
water with 8 mL of conc. HCl. The mixture was refluxed for 18 h, cooled and filtered. The hydrochloride 
salt of 3 was dissolved in water on heating and the resulting solution was filtered hot and basified with 5% 
NaOH solution. After stirring for 10 min and cooling, the precipitate was filtered and washed with water. 
The product (3) was purified by reprecipitation from the hot solution in 5% HCl using 5% NaOH. The 
analytical sample was recrystallized from EtOH. Yield 74%; mp 198°C (lit.,16 mp 202-204°C).  
1H NMR (300 MHz, DMSO-d6): δ 4.32 (2H, s, C(4)H2), 5.93 (1H, br s, NH), 6.67 (1H, d, J = 7.9 Hz, H-8), 
6.72 (1H, t, J = 7.5 Hz, H-6), 6.94 (4H, br s, NHC(=NH)NH2), 7.01 (1H, d, J = 7.2 Hz, H-5), 7.05 (1H, t, 
J = 7.5 Hz, H-7).  
 
13C NMR (75 MHz, DMSO-d6): δ 42.8 (br s, C-4), 120.3 (C-8), 120.6 (C-4a), 121.1 (br s, C-8), 125.0 (C-6), 
127.0 (C-7), 145.3 (br s, C-8a), 159.5 (NHC(=NH)NH2), 159.9 (br s, C-2).  
 
2-Amino-4,4-dimethyl-4,6-dihydro-1(3)(11)H-[1,3,5]triazino[2,1-b]quinazoline (5).  
To suspension of 3,4-dihydroquinazolin-2-yl guanidine (3, 0.47 g, 2.5 mmol) in acetone (10 mL), 
piperidine (0.2 mL) was added. The reaction mixture was heated under reflux for 18 h. After cooling, the 
product (5) was filtered and recrystallized from a mixture of acetone and EtOH. Yield 62%; mp 246°C.  
1H NMR (300 MHz, DMSO-d6): δ 1.37 (6H, s, 2Me), 4.45 (2H, s, C(6)H2), 6.35 (2H, br s, NH2), 6.77 (1H, 
d, J = 7.9 Hz, H-10), 6.81 (1H, t, J = 7.5 Hz, H-8), 7.01 (1H, d, J = 7.9 Hz, H-7), 7.05 (1H, t, J = 7.5 Hz, 
H-9).  
13C NMR (75 MHz, DMSO-d6): δ 27.0 (2Me), 42.7 (C-6), 71.2 (br s, C-4), 117.1 (br s, C-10), 119.7 (C-6a), 
120.8 (C-8), 125.4 (C-9), 127.6 (C-7), 140.4 (br s, C-10a), 151.5 (C-2), 153.4 (br s, C-11a).  
Anal. Calcd for C12H15N5: C, 62.86; H, 6.59; N, 30.54. Found: C, 62.75; H, 6.68; N, 30.37. 
 
General Procedure for Synthesis of 2-Amino-4-(het)aryl-4,6-dihydro-1(3)(11)H-[1,3,5]triazino- 
[2,1-b]quinazolines (7). To solution of 3,4-dihydroquinazolin-2-yl guanidine (3, 0.47 g, 2.5 mmol) in 
EtOH (7 mL), appropriate aldehyde (2.5 mmol) and piperidine (0.2 mL) were added. After heating under 
reflux for 4-18 h, the reaction mixture was cooled. The product (7) was filtered and recrystallized from a 
suitable solvent.  
 
2-Amino-4-phenyl-4,6-dihydro-1(3)(11)H-[1,3,5]triazino[2,1-b]quinazoline (7a).  
Yield 85%; mp 219-220°C (EtOH). 
1H NMR (300 MHz, DMSO-d6): δ 3.97 (1H, d, Jgem = 14.3 Hz, HA-6), 4.34 (1H, d, Jgem = 14.3 Hz, HM-6), 
5.50 (1H, s, H-4), 6.09 (2H, br s, NH2), 6.79 (1H, t, J = 7.3 Hz, H-8), 6.82 (1H, d, J = 7.3 Hz, H-10), 6.90 
(1H, d, J = 7.3 Hz, H-7), 7.06 (1H, t, J = 7.3 Hz, H-9), 7.23-7.46 (5H, m, Ph).  
13C NMR (75 MHz, DMSO-d6): δ 45.8 (C-6), 74.0 (br s, C-4), 117.0 (br s, C-10), 118.7 (C-6a), 121.3 (C-8), 
125.5 (C-9), 126.4 (C-2’ and C-6’), 127.8, 127.9 (C-7 and C-4’), 128.5 (C-3’ and C-5’), 139.3 (br s, C-10a), 
142.6 (C-1’), 151.3 (C-2), 153.9 (br s, C-11a).  
Anal. Calcd for C16H15N5: C, 69.29; H, 5.45; N, 25.25. Found: C, 69.02; H, 5.62; N, 25.03. 
 
2-Amino-4-(4-chlorophenyl)-4,6-dihydro-1(3)(11)H-[1,3,5]triazino[2,1-b]quinazoline (7b). 
Yield 84%; mp 156°C (EtOH). 
1H NMR (300 MHz, DMSO-d6): δ 3.95 (1H, d, Jgem = 14.3 Hz, HA-6), 4.33 (1H, d, Jgem = 14.3 Hz, HM-6), 
5.53 (1H, s, H-4), 5.59 (2H, br s, NH2), 6.81 (1H, t, J = 7.2 Hz, H-8), 6.83 (1H, d, J = 7.5 Hz, H-10), 6.94 
 
(1H, d, J = 7.2 Hz, H-7), 7.09 (1H, t, J = 7.3 Hz, H-9), 7.38 (2H, d, J = 8.3 Hz, H-2’ and H-6’), 7.43 (2H, d, 
J = 8.3 Hz, H-3’ and H-5’), 9.51 (1H, br s, NH).  
13C NMR (75 MHz, DMSO-d6): δ 45.6 (C-6), 74.1 (br s, C-4), 116.1 (br s, C-10), 118.3 (C-6a), 121.3 (C-8), 
125.6 (C-9), 127.9 (C-7), 128.2 (C-2’ and C-6’), 128.4 (C-3’ and C-5’), 132.2 (C-4’), 138.2 (br s, C-10a), 
142.0 (br s, C-1’), 151.3 (C-2), 154.4 (br s, C-11a).  
Anal. Calcd for C16H14N5Cl: C, 61.64; H, 4.53; N, 22.46. Found: C, 61.52; H, 4.63; N, 22.35. 
 
2-Amino-4-(4-bromophenyl)-4,6-dihydro-1(3)(11)H-[1,3,5]triazino[2,1-b]quinazoline (7c).  
Yield 87%; mp 164°C (EtOH). 
1H NMR (300 MHz, DMSO-d6): δ 3.95 (1H, d, Jgem = 14.7 Hz, HA-6), 4.33 (1H, d, Jgem = 14.7 Hz, HM-6), 
5.51 (1H, s, H-4), 5.68 (2H, br s, NH2), 6.80 (1H, t, J = 7.3 Hz, H-8), 6.83 (1H, d, J = 7.9 Hz, H-10), 6.93 
(1H, d, J = 7.2 Hz, H-7), 7.08 (1H, t, J = 7.5 Hz, H-9), 7.32 (2H, d, J = 8.3 Hz, H-2’ and H-6’), 7.57 (2H, d, 
J = 8.3 Hz, H-3’ and H-5’), 9.55 (1H, br s, NH).  
13C NMR (75 MHz, DMSO-d6): δ 45.7 (C-6), 74.0 (br s, C-4), 116.3 (br s, C-10), 118.4 (C-6a), 120.8 
(C-4’), 121.3 (C-8), 125.6 (C-9), 127.9 (C-7), 128.6 (C-2’ and C-6’), 131.3 (C-3’ and C-5’), 138.4 (br s, 
C-10a), 142.4 (br s, C-1’), 151.3 (C-2), 154.3 (br s, C-11a).  
H).  
Anal. Calcd for C16H14N5Br: C, 53.95; H, 3.96; N, 19.66. Found: C, 53.77; H, 3.98; N, 19.54. 
 
2-Amino-4-(4-methylphenyl)-4,6-dihydro-1(3)(11)H-[1,3,5]triazino[2,1-b]quinazoline (7d).  
Yield 72%; mp 179-180°C (MeOH). 
1H NMR (300 MHz, DMSO-d6): δ 2.28 (3H, s, Me), 3.94 (1H, d, Jgem = 14.3 Hz, HA-6), 4.30 (1H, d, Jgem = 
14.3 Hz, HM-6), 5.44 (1H, s, H-4), 5.68 (2H, br s, NH2), 6.78 (1H, t, J = 7.3 Hz, H-8), 6.80 (1H, d, J = 7.9 
Hz, H-10), 6.90 (1H, d, J = 7.2 Hz, H-7), 7.06 (1H, t, J = 7.5 Hz, H-9), 7.17 (2H, d, J = 7.9 Hz, H-3’ and 
H-5’), 7.25 (2H, d, J = 7.9 Hz, H-2’ and H-6’), 9.38 (1H, br s, N
13C NMR (75 MHz, DMSO-d6): δ 20.6 (Me), 45.6 (C-6), 74.2 (br s, C-4), 116.6 (br s, C-10), 118.6 (C-6a), 
121.2 (C-8), 125.5 (C-9), 126.3 (C-2’ and C-6’), 127.8 (C-7), 128.9 (C-3’ and C-5’), 137.0 (C-4’), 138.9 
(br s, C-10a), 139.9 (br s, C-1’), 151.3 (C-2), 153.9 (br s, C-11a).  
Anal. Calcd for C17H17N5: C, 70.08; H, 5.88; N, 24.04. Found: C, 69.89; H, 5.95; N, 23.86. 
 
2-Amino-4-(4-methoxyphenyl)-4,6-dihydro-1(3)(11)H-[1,3,5]triazino[2,1-b]quinazoline (7e).  
Yield 58%; mp 215-216°C (AcOEt). 
1H NMR (300 MHz, DMSO-d6): δ 3.73 (3H, s, OMe), 3.95 (1H, d, Jgem = 14.3 Hz, HA-6), 4.31 (1H, d, 
Jgem = 14.3 Hz, HM-6), 5.42 (1H, s, H-4), 6.23 (2H, br s, NH2), 6.77 (1H, t, J = 8.3 Hz, H-8), 6.78 (1H, d, 
 
J = 8.3 Hz, H-10), 6.88 (1H, d, J = 7.5 Hz, H-7), 6.93 (2H, d, J = 8.3 Hz, H-3’ and H-5’), 7.04 (1H, t, J = 7.3 
Hz, H-9), 7.31 (2H, d, J = 8.3 Hz, H-2’ and H-6’), 9.35 (1H, br s, NH).  
13C NMR (75 MHz, DMSO-d6): δ 45.8 (C-6), 55.0 (OMe), 73.4 (br s, C-4), 113.8 (C-3’ and C-5’), 117.4 
(br s, C-10), 118.9 (C-6a), 121.2 (C-8), 125.4 (C-9), 127.7 (C-2’ and C-6’), 127.8 (C-7), 134.6 (br s, C-1’), 
140.0 (br s, C-10a), 151.2 (br s, C-2), 153.6 (br s, C-11a), 159.0 (C-4’).  




Yield 75%; mp 212-214°C (EtOH).  
1H NMR (300 MHz, DMSO-d6): δ 2.87 (6H, s, NMe2), 3.96 (1H, d, Jgem = 14.3 Hz, HA-6), 4.27 (1H, d, 
Jgem = 14.3 Hz, HM-6), 5.32 (1H, s, H-4), 6.22 (2H, br s, NH2), 6.70 (2H, d, J = 8.7 Hz, H-3’ and H-5’), 6.75 
(1H, t, J = 7.9 Hz, H-8), 6.76 (1H, d, J = 7.9 Hz, H-10), 6.86 (1H, d, J = 7.2 Hz, H-7), 7.03 (1H, t, J = 7.3 Hz, 
H-9), 7.19 (2H, d, J = 8.7 Hz, H-2’ and H-6’), 9.37 (1H, br s, NH).  
13C NMR (75 MHz, DMSO-d6): δ 40.0 (NMe2), 45.7 (C-6), 73.5 (br s, C-4), 112.1 (C-3’ and C-5’), 117.5 
(br s, C-10), 119.0 (C-6a), 121.0 (C-8), 125.3 (C-9), 127.3 (C-2’ and C-6’), 127.7 (C-7), 129.7 (br s, C-1’), 
141.0 (br s, C-10a), 150.2 (C-4’), 151.3 (br s, C-2), 153.5 (br s, C-11a).  
Anal. Calcd for C18H20N6: C, 67.48; H, 6.29; N, 26.23. Found: C, 67.12; H, 6.49; N, 25.82. 
 
2-Amino-4-(2-thienyl)-4,6-dihydro-1(3)(11)H-[1,3,5]triazino[2,1-b]quinazoline (7g).  
Yield 82%; mp 214-215°C (EtOH).  
1H NMR (300 MHz, DMSO-d6): δ 4.17 (1H, d, Jgem = 14.3 Hz, HA-6), 4.40 (1H, d, Jgem = 14.3 Hz, HM-6), 
5.81 (1H, s, H-4), 5.91 (2H, br s, NH2), 6.82 (1H, t, J = 7.2 Hz, H-8), 6.83 (1H, d, J = 7.5 Hz, H-10), 6.95 
(1H, dd, J = 4.7, 3.7 Hz, H-4’), 6.98 (1H, d, J = 7.2 Hz, H-7), 7.08 (1H, t, J = 7.3 Hz, H-9), 7.10 (1H, d, J = 
3.7 Hz, H-3’), 7.43 (1H, d, J = 4.7 Hz, H-5’), 9.62 (1H, br s, NH).  
13C NMR (75 MHz, DMSO-d6): δ 45.6 (C-6), 70.1 (br s, C-4), 116.2 (br s, C-10), 118.7 (C-6a), 121.4 (C-8), 
124.8 (C-3’), 125.5, 125.6 (C-9 and C-5’), 126.1 (C-4’), 127.9 (C-7), 138.4 (br s, C-10a), 147.5 (br s, C-2’), 
150.9 (C-2), 155.0 (br s, C-11a).  
Anal. Calcd for C14H13N5S: C, 59.34; H, 4.62; N, 24.72. Found: C, 59.09; H, 4.86; N, 24.57. 
 
2-Amino-4-(3-pyridyl)-4,6-dihydro-1(3)(11)H-[1,3,5]triazino[2,1-b]quinazoline (7h).  
Yield 77%; mp 215-217°C (EtOH).  
1H NMR (300 MHz, DMSO-d6): δ 4.00 (1H, d, Jgem = 14.3 Hz, HA-6), 4.38 (1H, d, Jgem = 14.3 Hz, HM-6), 
5.62 (1H, s, H-4), 5.68 (2H, br s, NH2), 6.82 (1H, t, J = 7.3 Hz, H-8), 6.85 (1H, d, J = 7.2 Hz, H-10), 6.95 
 
(1H, d, J = 7.5 Hz, H-7), 7.10 (1H, t, J = 7.5 Hz, H-9), 7.40 (1H, dd, J = 7.7, 4.7 Hz, H-5’), 7.74 (1H, dd, J = 
7.5, 1.9 Hz, H-4’), 8.52 (1H, dd, J = 4.7, 1.5 Hz, H-6’), 8.57 (1H, d, J = 1.5 Hz, H-2’), 9.63 (1H, br s, NH).  
13C NMR (75 MHz, DMSO-d6): δ 45.7 (C-6), 72.8 (br s, C-4), 116.1 (br s, C-10), 118.4 (C-6a), 121.4 (C-8), 
123.8 (C-5’), 125.6 (C-9), 127.9 (C-7), 133.9 (C-4’), 138.1 (br s, C-10a), 138.2 (C-3’), 147.9 (C-2’), 149.1 
(C-6’), 151.4 (C-2), 154.7 (C-11a).  
Anal. Calcd for C15H14N6: C, 64.73; H, 5.07; N, 30.20. Found: C, 64.46; H, 5.43; N, 30.04. 
 
Reaction of 3,4-dihydroquinazolin-2-yl guanidine (3) with cycloketones in DMF 
To solution of 3,4-dihydroquinazolin-2-yl guanidine (3, 0.47 g, 2.5 mmol) in DMF (5 mL), appropriate 
cycloketone (5.0 mmol) was added. After heating under reflux for 4 h, the reaction mixture was cooled and 
evaporated to half of the volume. The product (9) was filtered and recrystallized from a suitable solvent.  
 
N-(6,7-Dihydro-5H-cyclopenta[d]pyrimidin-2-yl)-3,4-dihydroquinazolin-2-amine (9a). 
Yield 46%; mp > 300°C (DMF).  
1H NMR (300 MHz, DMSO-d6): δ 2.01 (2H, quintet, J = 7.5 Hz, C(6’)H2), 2.74-2.86 (4H, m, C(5’)H2 and 
C(7’)H2), 4.52 (2H, s, C(6)H2), 6.89 (1H, t, J = 7.0 Hz, H-6), 6.90 (1H, d, J = 7.2 Hz, H-8), 7.08 (1H, d, J = 
7.5 Hz, H-5), 7.13 (1H, t, J = 7.5 Hz, H-7), 8.28 (1H, s, H-4’), 9.86 (2H, br s, 2NH).  
13C NMR (75 MHz, DMSO-d6): δ 22.3 (C-6), 27.1 (CH2), 33.6 (CH2), 41.6 (C(6)H2), 115.0 (C-8), 118.6 
(C-6a), 121.4 (C-6), 124.5 (C-4a’), 125.5 (C-7), 127.7 (C-5), 137.7 (C-8a), 151.3 (C-4’), 152.9 (C-2), 164.1 
(C-7a’), 174.8 (C-2’).  
Anal. Calcd for C15H15N5: C, 67.90; H, 5.70; N, 26.40. Found: C, 67.67; H, 5.96; N, 26.15. 
 
N-(5,6,7,8-Tetrahydroquinazolin-2-yl)-3,4-dihydroquinazolin-2-amine (9b). 
Yield 62%; mp 227°C (EtOH).  
1H NMR (300 MHz, DMSO-d6): δ 1.60-1.88 (4H, m, C(6’)H2 and C(7’)H2), 2.58 (2H, t, J = 6.0 Hz, 
C(5’)H2), 2.69 (2H, t, J = 6.0 Hz, C(8’)H2), 4.51 (2H, s, C(6)H2), 6.88 (1H, d, J = 7.5 Hz, H-8), 6.89 (1H, t, 
J = 7.2 Hz, H-6), 7.08 (1H, d, J = 7.5 Hz, H-5), 7.13 (1H, t, J = 7.5 Hz, H-7), 8.18 (1H, s, H-4’), 9.80 (2H, 
br s, 2NH).  
13C NMR (75 MHz, DMSO-d6): δ 21.9 (CH2), 22.1 (CH2), 24.3 (CH2), 31.4 (CH2), 41.6 (C(6)H2), 114.9 
(C-8), 118.6 (C-6a), 120.1 (C-4a’), 121.4 (C-6), 125.6 (C-7), 127.7 (C-5), 137.7 (C-8a), 152.9 (C-2), 157.2 
(C-4’), 163.0 (C-8a’), 164.5 (C-2’). 
Anal. Calcd for C16H17N5: C, 68.79; H, 6.13; N, 25.07. Found: C, 68.52; H, 6.28; N, 24.82. 
 
2-Amino-6H-[1,3,5]triazino[2,1-b]quinazoline (10).  
 
Method A. A solution of 3,4-dihydroquinazolin-2-yl guanidine (3, 0.47 g, 2.5 mmol) and triethyl 
orthoformate (0.5 mL, 3 mmol) in DMF (5 mL) was heated under reflux for 4 h. After cooling, the yellow 
precipitate was filtered, washed with EtOH and recrystallized from DMF. 
Method B. A mixture of 3,4-dihydroquinazolin-2-yl guanidine (3, 0.47 g, 2.5 mmol) and diethyl 
ethoxymethylenemalonate (0.5 mL, 2.5 mmol) in MeCN (10 mL) was heated under reflux for 7 h. After 
cooling, precipitated product was filtered, washed with EtOH and recrystallized from DMF to provide 
compound identical to the sample obtained in Method A.  
Yield 63% (Method A), 82% (Method B); mp 294-295°C.  
1H NMR (300 MHz, DMSO-d6): δ 4.99 (2H, s, C(6)H2), 6.80 (1H, d, J = 7.9 Hz, H-10), 6.85 (1H, t, J = 
7.5 Hz, H-8), 6.98 (1H, d, J = 7.2 Hz, H-7), 7.08 (1H, t, J = 7.5 Hz, H-9), 7.20 (1H, s, NH), 7.24 (1H, s, NH), 
7.97 (1H, s, H-4).  
13C NMR (75 MHz, DMSO-d6): δ 47.9 (C-6), 119.1 (C-6a), 121.7 (C-10), 122.6 (C-8), 124.9 (C-9), 128.0 
(C-7), 143.9 (C-10a), 148.1 (C-2), 157.3 (C-4), 162.6 (C-11a).  
Anal. Calcd for C10H9N5: C, 60.29; H, 4.55; N, 35.16. Found: C, 60.23; H, 4.58; N, 35.10. 
 
2-Amino-6H-[1,3,5]triazino[2,1-b]quinazolin-4-thione (12). 
3,4-Dihydroquinazolin-2-yl guanidine (3, 0.47 g, 2.5 mmol) and carbon disulphide (1.0 mL, 16 mmol) were 
added to pyridine (4.0 mL) and refluxed for 5 h. After cooling, the product was filtered, washed with MeOH 
and recrystallized from DMF. Yield 52%; mp > 300°C. 
IR (KBr, ν, cm-1): NH 3470, NH 3267, NH 3171, CHAr 3080, 1636, 1607, 1578, 1541, 1508, 1479, 1450, 
1406, 1337, 1246, C=S 1186, 1111, 982, 820, 768, 758, 451.  
1H NMR (300 MHz, DMSO-d6): δ 5.40 (2H, s, C(6)H2), 7.00 (1H, d, J = 7.9 Hz, H-10), 7.02 (1H, t, J = 
7.5 Hz, H-8), 7.18 (1H, s, NH), 7.22 (1H, t, J = 7.9 Hz, H-9), 7.25 (1H, d, J = 7.5 Hz, H-7), 7.46 (1H, s, NH), 
10.65 (1H, s, NH).  
13C NMR (75 MHz, DMSO-d6): δ 47.9 (C-6), 114.3 (C-10), 117.8 (C-6a), 123.2 (C-8), 126.3 (C-9), 128.3 
(C-7), 133.8 (C-10a), 152.7 (C-2), 160.4 (C-11a), 182.8 (C-4).  
Anal. Calcd for C10H9N5S: C, 51.93; H, 3.92; N, 30.28. Found: C, 51.71; H, 3.98; N, 30.09. 
 
2,4-Diamino-[1,3,5]triazino[1,2-a]benzimidazole hydrochloride (16a). 
Benzimidazol-2-yl guanidine (1, 0.44 g, 2.5 mmol) and trichloroacetonitrile (0.35 mL, 3.5 mmol) was 
added to EtOH (7 mL) and refluxed for 8 h. After cooling, the product (15a) was filtered and resuspended in 
aqueous HCl (0.5 M, 5 mL). The solid was dissolved on heating and the resulting solution was filtered hot. 
After cooling, the hydrochloride salt (16a) was filtered and recrystallized from water. Yield 72%; mp > 
300°C.  
 
1H NMR (300 MHz, DMSO-d6): δ 7.40 (1H, t, J = 7.3 Hz, H-7), 7.48-7.59 (2H, m, H-8, and H-9), 7.98 (1H, 
s, NH), 8.11 (1H, s, NH), 8.63 (1H, d, J = 7.3 Hz, H-6), 8.63 (2H, br s, NH), 13.83 (1H, s, NH+).  
13C NMR (75 MHz, DMSO-d6): δ 111.9 (C-6), 114.0 (C-9), 122.7 (C-7), 124.0 (C-8), 126.6 (C-5a), 129.9 
(C-9a), 151.6, 151.9 (C-2 and C-10a), 162.9 (C-4).  
Anal. Calcd for C9H9N6Cl: C, 45.68; H, 3.83; N, 35.51. Found: C, 45.53; H, 4.00; N, 35.28. 
 
6H-[1,3,5]Triazino[2,1-b]quinazolin-2,4-diamine hydrochloride (16b). 
3,4-Dihydroquinazolin-2-yl guanidine (3, 0.47 g, 2.5 mmol) and trichloroacetonitrile (0.35 mL, 3.5 mmol) 
was added to EtOH (7 mL) and refluxed for 8 h. After cooling, the product (15b) was filtered and 
resuspended in EtOH (5 mL) and aqueous HCl (1.0 M, 2.5 mL). The solid was dissolved on heating and the 
resulting solution was filtered hot. After cooling, the hydrochloride salt (16b) was filtered and 
recrystallized from water. Yield 68%; mp > 300°C.  
1H NMR (300 MHz, DMSO-d6): δ 5.12 (2H, s, C(6)H2), 7.04-7.17 (3H, m, H-7, H-8 and H-10), 7.21-7.32 
(1H, m, H-9), 7.76 (1H, s, NH), 7.78 (1H, s, NH), 8.38 (1H, br s, NH), 8.49 (1H, br s, NH), 11.21 (1H, s, 
NH+).  
13C NMR (75 MHz, DMSO-d6): δ 45.3 (C-6), 115.1 (C-10), 116.1 (C-6a), 123.7 (C-8), 125.7 (C-9), 128.7 
(C-7), 132.6 (C-10a), 151.4 (C-2), 156.3 (C-4), 163.1 (C-11a).  
Anal. Calcd for C10H11N6Cl: C, 47.91; H, 4.42; N, 33.52. Found: C, 47.74; H, 4.56; N, 33.38. 
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